Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Biomarkers Advanced Technologies Market

ID: MRFR/HC/20202-HCR
128 Pages
Rahul Gotadki
Last Updated: April 06, 2026

United States Biomarkers Advanced Technologies Market Research Report Information By Application (Risk Assessment, Development of Molecular Diagnostics, Disease Diagnosis, Drug Discovery and Development, Drug Formulation, Forensic Application, Others (DNA fingerprinting and others)), By Indication (Cancer, Infectious Diseases, Immune Disorders, Neurological Disorders, Cardiovascular Disorders, Other Disease Indications), By End User (Pharmaceutical and Biotechnology Companies, Diagnostics and Research Laboratories, Hospitals, Specialty Clinics, Others)– United States Market Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Biomarkers Advanced Technologies Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Application (USD Billion)
  49.     4.1.1 Oncology
  50.     4.1.2 Cardiology
  51.     4.1.3 Neurology
  52.     4.1.4 Infectious Diseases
  53.     4.1.5 Metabolic Disorders
  54.   4.2 Healthcare, BY Technology (USD Billion)
  55.     4.2.1 Genomics
  56.     4.2.2 Proteomics
  57.     4.2.3 Metabolomics
  58.     4.2.4 Immunoassays
  59.     4.2.5 Bioinformatics
  60.   4.3 Healthcare, BY End Use (USD Billion)
  61.     4.3.1 Pharmaceutical Companies
  62.     4.3.2 Research Institutions
  63.     4.3.3 Diagnostic Laboratories
  64.     4.3.4 Clinical Laboratories
  65.     4.3.5 Biotechnology Companies
  66. 5 SECTION V: COMPETITIVE ANALYSIS
  67.   5.1 Competitive Landscape
  68.     5.1.1 Overview
  69.     5.1.2 Competitive Analysis
  70.     5.1.3 Market share Analysis
  71.     5.1.4 Major Growth Strategy in the Healthcare
  72.     5.1.5 Competitive Benchmarking
  73.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  74.     5.1.7 Key developments and growth strategies
  75.       5.1.7.1 New Product Launch/Service Deployment
  76.       5.1.7.2 Merger & Acquisitions
  77.       5.1.7.3 Joint Ventures
  78.     5.1.8 Major Players Financial Matrix
  79.       5.1.8.1 Sales and Operating Income
  80.       5.1.8.2 Major Players R&D Expenditure. 2023
  81.   5.2 Company Profiles
  82.     5.2.1 Thermo Fisher Scientific (US)
  83.       5.2.1.1 Financial Overview
  84.       5.2.1.2 Products Offered
  85.       5.2.1.3 Key Developments
  86.       5.2.1.4 SWOT Analysis
  87.       5.2.1.5 Key Strategies
  88.     5.2.2 Roche Diagnostics (US)
  89.       5.2.2.1 Financial Overview
  90.       5.2.2.2 Products Offered
  91.       5.2.2.3 Key Developments
  92.       5.2.2.4 SWOT Analysis
  93.       5.2.2.5 Key Strategies
  94.     5.2.3 Abbott Laboratories (US)
  95.       5.2.3.1 Financial Overview
  96.       5.2.3.2 Products Offered
  97.       5.2.3.3 Key Developments
  98.       5.2.3.4 SWOT Analysis
  99.       5.2.3.5 Key Strategies
  100.     5.2.4 Illumina (US)
  101.       5.2.4.1 Financial Overview
  102.       5.2.4.2 Products Offered
  103.       5.2.4.3 Key Developments
  104.       5.2.4.4 SWOT Analysis
  105.       5.2.4.5 Key Strategies
  106.     5.2.5 Agilent Technologies (US)
  107.       5.2.5.1 Financial Overview
  108.       5.2.5.2 Products Offered
  109.       5.2.5.3 Key Developments
  110.       5.2.5.4 SWOT Analysis
  111.       5.2.5.5 Key Strategies
  112.     5.2.6 Bio-Rad Laboratories (US)
  113.       5.2.6.1 Financial Overview
  114.       5.2.6.2 Products Offered
  115.       5.2.6.3 Key Developments
  116.       5.2.6.4 SWOT Analysis
  117.       5.2.6.5 Key Strategies
  118.     5.2.7 PerkinElmer (US)
  119.       5.2.7.1 Financial Overview
  120.       5.2.7.2 Products Offered
  121.       5.2.7.3 Key Developments
  122.       5.2.7.4 SWOT Analysis
  123.       5.2.7.5 Key Strategies
  124.     5.2.8 Qiagen (US)
  125.       5.2.8.1 Financial Overview
  126.       5.2.8.2 Products Offered
  127.       5.2.8.3 Key Developments
  128.       5.2.8.4 SWOT Analysis
  129.       5.2.8.5 Key Strategies
  130.     5.2.9 Merck KGaA (US)
  131.       5.2.9.1 Financial Overview
  132.       5.2.9.2 Products Offered
  133.       5.2.9.3 Key Developments
  134.       5.2.9.4 SWOT Analysis
  135.       5.2.9.5 Key Strategies
  136.     5.2.10 SAB Biotherapeutics (US)
  137.       5.2.10.1 Financial Overview
  138.       5.2.10.2 Products Offered
  139.       5.2.10.3 Key Developments
  140.       5.2.10.4 SWOT Analysis
  141.       5.2.10.5 Key Strategies
  142.   5.3 Appendix
  143.     5.3.1 References
  144.     5.3.2 Related Reports
  145. 6 LIST OF FIGURES
  146.   6.1 MARKET SYNOPSIS
  147.   6.2 US MARKET ANALYSIS BY APPLICATION
  148.   6.3 US MARKET ANALYSIS BY TECHNOLOGY
  149.   6.4 US MARKET ANALYSIS BY END USE
  150.   6.5 KEY BUYING CRITERIA OF HEALTHCARE
  151.   6.6 RESEARCH PROCESS OF MRFR
  152.   6.7 DRO ANALYSIS OF HEALTHCARE
  153.   6.8 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  154.   6.9 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  155.   6.10 SUPPLY / VALUE CHAIN: HEALTHCARE
  156.   6.11 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  157.   6.12 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  158.   6.13 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
  159.   6.14 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
  160.   6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
  161.   6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
  162.   6.17 BENCHMARKING OF MAJOR COMPETITORS
  163. 7 LIST OF TABLES
  164.   7.1 LIST OF ASSUMPTIONS
  165.     7.1.1
  166.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  167.     7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  168.     7.2.2 BY TECHNOLOGY, 2026-2035 (USD Billion)
  169.     7.2.3 BY END USE, 2026-2035 (USD Billion)
  170.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  171.     7.3.1
  172.   7.4 ACQUISITION/PARTNERSHIP
  173.     7.4.1

US Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2026-2035)

  • Oncology
  • Cardiology
  • Neurology
  • Infectious Diseases
  • Metabolic Disorders

Healthcare By Technology (USD Billion, 2026-2035)

  • Genomics
  • Proteomics
  • Metabolomics
  • Immunoassays
  • Bioinformatics

Healthcare By End Use (USD Billion, 2026-2035)

  • Pharmaceutical Companies
  • Research Institutions
  • Diagnostic Laboratories
  • Clinical Laboratories
  • Biotechnology Companies

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $ $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions